BioSpace News Archive

DURECT Corporation announced financial results for the three months ended March 31, 2021 and provided a corporate update.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2021

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following virtual conferences in May

Successful listing on TSXV advances Small Pharma’s bold vision to revolutionize the treatment of patients with mental health conditions through psychedelic-assisted therapies

Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, led by its Orascovery platform, today announced that it has acquired Kuur Therapeutics, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 3, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 14,500 shares of Puma common stock to three new non-executive employees.

KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced an important milestone, PrCORZYNA™

Company sees this new dosing regimen of 60 pills over 5 days as optimal for Tollovid, the Company’s 3CL protease inhibitor botanical dietary supplement that helps to support and maintain healthy immune function

Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering RNA cell therapy in and beyond oncology, today announced a $2 million competitive R&D award from the National Heart Lung and Blood Institute

Jaguar Gene Therapy , a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, today announced the appointment of Joseph W. McIntosh, M.D., as Chief Medical Officer. Dr. McIntosh joins Jaguar with more than 16 years of drug development experience in the biopharmaceutical industry, with a focus on developing gene therapies.